SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome.

Drexel, H; Coats, AJS; Spoletini, I; Bilato, C; Mollace, V; Perrone Filardi, P; Rosano, GMC (2020) An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome. Eur Heart J Cardiovasc Pharmacother, 6 (2). pp. 115-121. ISSN 2055-6845 https://doi.org/10.1093/ehjcvp/pvz079
SGUL Authors: Rosano, Giuseppe Massimo Claudio

[img]
Preview
PDF Accepted Version
Available under License ["licenses_description_publisher" not defined].

Download (975kB) | Preview

Abstract

Benefits and safety on statins have been well-established over 20 years of research. Despite this, the vast majority of patients are not adequately treated and do not achieve the low-density lipoprotein cholesterol target levels. This is mainly due to poor adherence, which is associated with dangerous and sometimes fatal outcomes. To increase adherence and prevent worse outcomes, a combination therapy with lower dosage of statins and new lipid-lowering drugs may be used. However, the implementation of new lipid-lowering drugs in European countries is still at the beginning. For these reasons, the aim of this position paper is to give an up-to-date indication from the ESC Working Group on Cardiovascular Pharmacotherapy in order to discuss the barriers towards statins adherence and new lipid-lowering drugs implementation in Europe.

Item Type: Article
Additional Information: This is a pre-copyedited, author-produced version of an article accepted for publication in European Heart Journal: Cardiovascular Pharmacotherapy following peer review. The version of record Heinz Drexel, Andrew J S Coats, Ilaria Spoletini, Claudio Bilato, Vincenzo Mollace, Pasquale Perrone Filardi, Giuseppe M C Rosano, An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome, European Heart Journal - Cardiovascular Pharmacotherapy, Volume 6, Issue 2, March 2020, Pages 115–121 is available online at: https://doi.org/10.1093/ehjcvp/pvz079 Corrigendum available at https://doi.org/10.1093/ehjcvp/pvaa069
Keywords: Ezetimibe, Low-density lipoprotein cholesterol, PCSK9 inhibitors, Position paper, Statin intolerance, Statins adherence, Anticholesteremic Agents, Biomarkers, Cardiovascular Diseases, Cholesterol, LDL, Down-Regulation, Drug Therapy, Combination, Dyslipidemias, Ezetimibe, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Medication Adherence, Proprotein Convertase 9, Risk Assessment, Risk Factors, Serine Proteinase Inhibitors, Treatment Outcome, Humans, Cardiovascular Diseases, Anticholesteremic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Serine Proteinase Inhibitors, Treatment Outcome, Drug Therapy, Combination, Risk Assessment, Risk Factors, Down-Regulation, Dyslipidemias, Cholesterol, LDL, Medication Adherence, Biomarkers, Ezetimibe, Proprotein Convertase 9, PCSK9 inhibitors, Statins adherence, ezetimibe, low-density lipoprotein cholesterol, position paper, statin intolerance
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Eur Heart J Cardiovasc Pharmacother
ISSN: 2055-6845
Language: eng
Dates:
DateEvent
1 April 2020Published
24 December 2019Published Online
20 December 2019Accepted
Publisher License: Publisher's own licence
PubMed ID: 31873726
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/111911
Publisher's version: https://doi.org/10.1093/ehjcvp/pvz079

Actions (login required)

Edit Item Edit Item